We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00263159
Recruitment Status : Completed
First Posted : December 7, 2005
Last Update Posted : December 28, 2007
Sponsor:
Information provided by:

December 6, 2005
December 7, 2005
December 28, 2007
January 2006
Not Provided
The difference between study groups in the change of asthma control from baseline and follow-up visits [ Time Frame: after 1, 3 and 6 months ]
The difference between study groups in the change of asthma control from baseline and follow-up visits (after 1, 3 and 6 months)
Complete list of historical versions of study NCT00263159 on ClinicalTrials.gov Archive Site
  • Peak flow [ Time Frame: after 3 and 6 months ]
  • Knowledge of asthma and treatment [ Time Frame: after 6 months ]
  • Asthma quality of life questionnaire (AQLQ) [ Time Frame: after 6 months ]
  • Therapy adherence
  • Inhalation techniques [ Time Frame: after 6 months ]
  • Smoking [ Time Frame: after 6 months ]
  • Asthma exacerbations [ Time Frame: after 6 months ]
  • General Practitioner (GP) visits, emergency room visits and hospitalisations
  • Working days lost and school days lost
  • Peak flow (after 3 and 6 months)
  • Knowledge of asthma and treatment (after 6 months)
  • Asthma quality of lifte AQLQ (after 6 months)
  • Therapy adherence (after 6 months)
  • Inhalation techniques (after 6 months)
  • Smoking (after 6 months)
  • Asthma exacerbations (after 6 months)
  • GP visits, emergency room visits and hospitalisations
  • Working days lost and school days lost
Not Provided
Not Provided
 
Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study
Pharmaceutical Care for Asthma Control Improvement
The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients.
The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients. Patients will be randomly allocated to the control group (= no input from pharmacist) or intervention group (= with pharmaceutical care at baseline and follow-up visits over 6 months).
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Asthma
Procedure: Pharmaceutical care for asthma patients
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
221
October 2006
Not Provided

Inclusion Criteria:

  • Patients with persistent asthma
  • Asthma treatment for at least 12 months
  • Regular visitors of the participating community pharmacy

Exclusion Criteria:

  • Severe co-morbidity
  • > 10 pack-years smoking history
  • Asthma Control Test score < 15 or =25
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Belgium
 
 
NCT00263159
2005/320
No
Not Provided
Not Provided
Not Provided
University Ghent
Not Provided
Principal Investigator: Guy Brusselle, MD, PhD University Hospital, Ghent
University Ghent
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP